NDL2 / QIMR Berghofer Medical Research Institute, Kazia - LARVOL DELTA

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) (PRNewswire-Asia) - "Across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity, including in combination with anti-PD-1 therapy. By applying targeted protein degradation to one of the most clinically validated targets in oncology (PD-L1), Kazia aims to address a fundamental limitation of current immunotherapies while advancing a program aligned with growing strategic interest in protein degraders."

Preclinical • Solid Tumor

Kazia Therapeutics…announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity securities (PIPE) (PRNewswire) - "Pursuant to the securities purchase agreement, the Company agreed to offer and sell to the investors an aggregate of approximately $50.0 million of ordinary shares and prefunded warrants, at a purchase price per share that is the equivalent of $5.00 per ADS, each ADS representing 500 ordinary shares....The Company currently intends to use the net proceeds from the offering...to support the continued clinical development of its lead program paxalisib..., advancing the PD-L1 degrader program, and for general corporate purposes."

Financing • Breast Cancer • CNS Tumor

NDL2 PD-L1 Degrader Program… (PRNewswire) - "As announced in September 2025, Kazia entered into a collaboration and licensing agreement with QIMR Berghofer covering the first in class NDL2 PD-L1 degrader program....This strategy may address resistance mechanisms that limit current checkpoint inhibitors. Kazia expects to initiate IND-enabling preclinical studies in early 2026."

Licensing / partnership • Preclinical • Oncology